RenovoRx (RNXT) Total Current Liabilities (2020 - 2026)
RenovoRx (RNXT) posted Total Current Liabilities of $1.9 million for Q1 2026, down 2.14% sequentially from $2.0 million in Q4 2025, and up 10.6% YoY from $1.7 million in Q1 2025.
RenovoRx (RNXT) Total Current Liabilities (2020 - 2026) Analysis & Trends
RenovoRx has reported Total Current Liabilities for 7 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Total Current Liabilities rose 10.6% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 10.6% YoY) and the FY2025 annual result came in at $2.0 million, up 2.78% from the prior year.
- Total Current Liabilities eased to $1.9 million in Q1 2026 per RNXT's latest filing, from $2.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $2.0 million in Q4 2025 and troughed at $1.1 million in Q1 2024.
- A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 62.47% in 2024, down 22.84% in 2024.
- Over 5 years, Total Current Liabilities stood at $1.1 million in 2022, then increased by 6.62% to $1.2 million in 2023, then surged by 62.47% to $1.9 million in 2024, then climbed by 2.78% to $2.0 million in 2025, then retreated by 2.14% to $1.9 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.9 million, $2.0 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 630.93 Mn |
| 10 | RenovoRx | 62.43 Mn | 62.43 Mn | 766,000.00 | 1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.88 Mn |
| Mar 31, 2026 | 1.92 Mn |
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.61 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 938,000.00 |
| Sep 30, 2021 | 625,000.00 |
| Dec 31, 2020 | 4.10 Mn |